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10 Abstract Cushing’s syndrome (CS) is a rare endocrine
11 disease, due to cortisol hypersecretion. CS patients have
12 comorbidities, often still present after biochemical cure.
13 Specific nursing healthcare programs to address this dis-
14 ease and achieve improved health related quality of life
15 (HRQoL) are lacking. Thus, an educational nursing inter-
16 vention, through the development and promotion of
17 specific educational tools, appears to be justified. The
18 objective of this study is to assess the effectiveness of an
19 educational nursing program in CS patients on HRQoL,
20 clinical parameters, level of pain and physical activity,
21 patterns of rest, and use of health resources. A prospective,
22 randomized study was conducted in two reference hospitals
23for CS. Sixty-one patients (mean age 47 ± 12.7 years,
2483.6 % females) were enrolled and divided into 2 groups:
25an ‘‘intervention’’ group where educational sessions were
26performed over 9 months and a ‘‘control’’ group, without
27these sessions. Specific questionnaires were used at the
28beginning and end of the study. After educational sessions,
29the intervention group had a better score in the Cush-
30ingQoL questionnaire (p\ 0.01), reduced level of pain
31(p\ 0.05), improved physical activity (p\ 0.01) and
32healthy lifestyle (p\ 0.001) compared to the control
33group. A correlation between the CushingQoL score and
34reduced pain (r = 0.46, p\ 0.05), improved physical
35activity (r = 0.89, p\ 0.01), and sleep (r = 0.53,
36p = 0.01) was observed. This educational nursing program
37improved physical activity, healthy lifestyle, better sleep
38patterns, and reduced pain in CS patients, influencing
39HRQoL and reducing consumption of health resources.
40Moreover, the brief nature of the program suggests it as a
41good candidate to be used in CS patients. 2
43Keywords Cushing’s syndrome ! Nursing ! Educational
44program ! Health-related quality of life
45Introduction
46Patients with cushing’s syndrome (CS) suffer from multi-
47ple comorbidities, mainly cardiovascular (hypertension,
48atherosclerosis, changes in heart functionality), and meta-
49bolic (dyslipidemia, central obesity, diabetes), as well as
50thrombotic disorders, bone disorders, cognitive and neu-
51ropsychological impairment, and impaired sexual function
52due to glucocorticoid (GC) excess [1–6].
53The assumption that resolution of hypercortisolism
54normalized comorbidities is currently questioned, since
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55 there is evidence that cured CS patients still have increased
56 morbidity and mortality despite endocrine control [7–9].
57 Most patients with CS develop metabolic syndrome, which
58 may persist after remission of hypercortisolism, con-
59 tributing to increased cardiovascular risk and deserve to be
60 treated according to common standard practice [7].
61 Awareness of this persistent increase in cardiovascular risk
62 in CS patients after endocrine cure leads to strict control of
63 improvable factors, including blood pressure, dyslipemia,
64 hyperglycemia, smoking, obesity, and prothrombotic state
65 [10].
66 There is ample evidence on the positive effect of edu-
67 cational nursing interventions in the management of each
68 of the comorbidities described above [11–14]. Educational
69 nursing interventions in chronic diseases like ischemic
70 heart disease, rheumatoid arthritis, osteoporosis, diabetes,
71 hypertension, etc., improve the outcome of these patients.
72 This sort of intervention reduces consumption of drugs,
73 changes dietary habits, and physical activity, favoring a
74 better self-management, increasing self-efficacy and self-
75 care [11, 12]. Health education not only informs the patient
76 and family about the disease but modifies their behavior by
77 adopting new life habits, in order to actively manage their
78 care [13–15]. Many studies confirm the important role of
79 nurses in education of diabetic patients to improve dietary
80 habits, control chronic diseases, and reduce cardiovascular
81 risk [16–23].
82 Health-related quality of life (HRQoL) in patients with
83 CS is also severely affected, especially in active disease
84 [24], and still impaired after cure of hypercortisolism [25,
85 26]; this limits social activity of patients and may increase
86 pain perception [27]. Since we were unaware of any edu-
87 cational program for patients with CS, we aimed to develop
88 a specific nursing educational program, with specific edu-
89 cational tools. We investigated their outcome after fol-
90 lowing the program, in a prospective randomized study.
91 Patients and methods
92 Patients
93 Patients with CS of pituitary or adrenal origin followed in 2
94 reference centers [Hospital Sant Pau (HSP) and Hospital
95 Clı´nic (HC)] were included in this multicenter, prospective,
96 randomized study.
97 Patients who did not attend 100 % of the educational
98 program sessions and those who for cognitive reasons or
99 psychiatric or neurological problems could not continue the
100 education sessions were excluded. All patients signed an
101 informed consent after study approval by the hospitals
102 Ethics Committee.
103Of the 137 patients treated in HSP and HC, 37 declined
104to participate. Of the remaining 100, 39 did not meet the
105inclusion criteria (30 did not accept to participate, and the
106remaining 9 patients had functional or psychiatric limita-
107tions). The final sample included 61 patients, 48 were of
108pituitary origin and 13 of adrenal origin.
109Of the final sample, 45 were considered cured (repeat-
110edly normal 24-h urinary-free cortisol, serum cortisol
111suppression after overnight 1 mg dexamethasone
112\50 nmol/L or adrenal insufficiency with hydrocortisone
113substitution therapy); 24 had undergone radiotherapy and
114nine suffered hypopituitarism. Sixteen were active, all on
115medical therapy with ketokonazole and eight also with
116metyrapone.
117Remission was re-confirmed in all patients after the
1189 months of follow up. No patients developed any recur-
119rence during that period. The two cohorts of patients had
120similar clinical characteristics, and no differences in
121duration of remission were present. The patients were
122followed up long term over the years, and they were not in
123the early phase of surgical remission. Moreover, eucorti-
124solemia was confirmed in all patients on medical therapy.
125Sociodemographic and clinical variables were collected
126during a clinical interview and included personal data, age,
127sex, education level, employment status, and social activ-
128ity. Anthropometric variables included weight, height,
129body mass index (BMI), waist, and hip circumference, and
130systolic and diastolic blood pressure. Details related to CS
131like type of surgery, size of the lesion, symptoms, treat-
132ments, and recurrence were also collected. Table 1 shows
133the baseline clinical characteristics of the study partici-
134pants. Table 2 shows urinary-free cortisol (UFC), ACTH
135values, and comorbidities at the end of the study.
136Patients were randomized into two groups: (1) Inter-
137vention group (31 patients), who followed a specific
138nursing interventional program and (2) Control group (30
139patients), who did not undergo the specific nursing inter-
140ventional program. This randomization was stratified by
141center, by a computer generation of random numbers.
142Nursing educational intervention
143The educational intervention was carried out over
1449 months in the University School of Nursing, HSP. There
145were 5 visits: 4 educational sessions and 1 last visit, when
146questionnaires were repeated and final data were collected.
147The 4 educational sessions lasted 2 h, with intervals
148between sessions of 30 to 40 days, with a compulsory
149attendance for all the sessions. The first educational session
150was named as ‘‘baseline’’ (visit 1), and the last was named
151as ‘‘final visit’’ (visit 4). The study finalized (visit 5, ‘‘end
152of study’’) 9 months after the baseline session. All educa-
153tional sessions were conducted by a nurse experienced in
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154 educational programs for secondary prevention of cardio-
155 vascular risk factors (CG). Schedule and contents of edu-
156 cational sessions are reported in Table 3.
157 There was a progression in the different contents and in
158 the patient’s autonomy in the management of the knowl-
159 edge of the disease, as indicated in Table 2. Educational
160 resources with reference material were offered to the
161 patient and family throughout the visits, and all the mate-
162 rials were in Spanish.
163 All questionnaires were administered at baseline (visit
164 1) and end of the study (visit 5), both to the control group
165 and to the intervention group by the nurse who conducted
166 the educational sessions. The time to complete all ques-
167 tionnaires was approximately one hour.
168 The intervention group received the educational pro-
169 gram progressively during 4 sessions; it included
170 knowledge on CS, comorbidities, treatments, general
171management, and autonomy in healthy lifestyles
172(Table 2). By contrast, the control group only attended
173their usual medical appointments, with the information
174given by their doctor during scheduled visits, without any
175specific monitoring program or educational intervention
176visits (‘‘treatment as usual’’).
177Three sessions were patients group sessions (2nd, 3rd,
178and 5th), attended only by the patients, and in the other two
179sessions (1st, 4th), the patients could be accompanied by
180their families (Table 2). The aim of these latter sessions
181was that the relatives participated in the learning process
182and in the promotion of healthier lifestyles.
183This specific nursing interventional program had four
184main priorities:
1851. To identify signs and symptoms of CS and their
186comorbidities.
Table 1 Baseline clinical
characteristics of study
participants
Total Control group Intervention group
Demographic data Number of patients 61 30 31
Males 10 5 5
Females 51 25 26
Age (mean ± SD) 47.25 ± 12.6 48.3 ± 13.2 46.1 ± 12.2
Educational level Incomplete
primary school
2 2 0
Primary school 22 8 13
Secondary school 18 8 10
University 19 12 8
Previous health education No 58 29 29
Yes 3 1 2
Type of Cushing’s Sd Pituitary 48 24 24
Adrenal 13 6 7
Disease duration (years) Mean ± SD 2.5 ± 1.5 2.7 ± 1.7 2.3 ± 1.3
Active/cured Number of patients 16/45 7/23 9/22
Urinary-free cortisol (UFC)
(nmol/24 h)
Mean ± SD 111.1 ± 78.2 104.3 ± 81.88 118.1 ± 77.52
ACTH (pg/mL) Mean ± SD 16.5 ± 17.0 18.9 ± 18.1 14.1 ± 14.9
Pituitary tumor size Number of patients 48 24 24
Macro/
microadenoma
2/46 1/23 1/23
Duration of remission in
cured patients (n = 45)
Years
(mean ± SD)
6.67 ± 5.19 7.37 ± 5.70 5.88 ± 4.61
Partial, hypopituitarism Number of patients 5 4 1
Total, hypopituitarism Number of patients 4 2 2
Hypertension Number of patients 23 8 15
Obesity Number of patients 29 12 17
Hypercholesterolemia Number of patients 33 16 17
Diabetes Number of patients 8 3 5
Depression Number of patients 13 4 9
Osteoporosis Number of patients 9 3 6
No differences in the clinical characteristics were evidenced between intervention and control groups
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187 2. To demonstrate and to learn capacity for self-control
188 and monitoring of specific comorbidities of CS.
189 3. To apply the acquired knowledge to improve outcome
190 of those comorbidities that negatively affect their long-
191 term prognosis.
192 4. To give the patients tools to facilitate the learning
193 process and its application.
194 Data collection and questionnaires
195 The variables studied, collected in both the control group
196 and intervention group at baseline (visit 1) and at the end of
197 the study (visit 5), were the following:
198 – Health-related quality of life (HRQoL) It was measured
199 with the CushingQoL questionnaire, specifically
200 designed for patients with CS, and demonstrated to be
201 feasible, reliable, and valid [24, 28].
202 – Level of pain measured with the Spanish Pain Question-
203 naire, a standard pain measurement instrument [29–31].
204 – Level of physical activity measured with the Interna-
205 tional Physical Activity Questionnaire (IPAQ) [32,
206 33]; it collects weekly physical activity measured in
207 METs (Metabolic Equivalent of Task). One MET is a
208 physiological measure expressing the energy cost of
209 physical activities. It is defined as the energy cost of
210 sitting quietly and is equivalent to a caloric con-
211 sumption of 1 kcal/kg/h. There are three levels of
212 physical activity: low, moderate, and high. It is
213 estimated that compared with sitting quietly, a
214 person’s caloric consumption is three to six times
215higher when being moderately active (3–6 METs)
216and more than 6 times higher when being vigorously
217active ([6 METs).
218– Level of rest or sleep measured with the Oviedo Sleep
219Questionnaire (OSQ) [34, 35] and with two specific
220questions asking for the number of hours of rest and for
221the self-reported satisfaction with rest (the answer was
222‘‘yes’’ or ‘‘no’’).
223– The use of health resources the number of hospital
224admissions during the study period, of unscheduled
225visits or outpatient visits to their own endocrinologist
226or other health providers, was included.
227– Level of nicotine dependence measured with the
228Fagerstrom Test for Nicotine Dependence (FTND) to
229evaluate smoking [36–39].
230– Erectile dysfunction measured with the Spanish version
231of the Index of Erectile Function (IIEF 5) [40].
232– Female sexual function measured with the Spanish
233version of the Female Sexual Functioning Inventory
234(FSFI) and with the Female Sexual Function Question-
235naire brief profile (B- PFSF) [41–43].
236– Compliance with nutritional habits measured with the
237Lifestyle Associated Questionnaire [44, 45].
238
239Statistical analysis
240Statistical analysis was performed using SAS version 9.3
241software program (SAS Institute, USA). The normality
242assumption was tested using the Kolmogorov -Smirnov
Table 2 Urinary-free cortisol,
ACTH values, and
comorbidities at the end of the
study
Total Control group Intervention group
Patients included in the study Number of
patients
61 30 31
Active/cured Number of
patients
16/45 7/23 9/22
Urinary-free cortisol (UFC)
(nmol/24 h)
Mean ± SD 113.66 ± 80.17 103.55 ± 84.51 121.75 ± 77.76
ACTH (pg/mL) Mean ± SD 16.99 ± 17.21 19.46 ± 19.23 14.63 ± 15.08
Hypertension Number of
patients
23 9 14
Obesity Number of
patients
28 12 16
Hypercholesterolemia Number of
patients
30 14 16
Diabetes Number of
patients
5 3 2
Depression Number of
patients
14 5 9
Osteoporosis Number of
patients
10 3 7
No differences were evidenced between intervention and control groups
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243 test. Categorical variables are indicated as percentages.
244 Quantitative variables are expressed as mean ± standard
245 deviation (SD). Student t test was used for quantitative
246 variables. Chi-square test or a Fisher test (when appropri-
247 ate) was used for categorical variables.
248 Two types of analyses were done for all variables: one
249 compared the differences between control group and
250 intervention group, firstly at baseline and secondly at the
251 end of the study. The other type of analysis compared the
252 changes within each group (on one hand control group and
253 on the other hand intervention group) in all the variables,
254 throughout the study. Both analyses used Student t tests.
255 Pearson test was used to find correlations between
256 variables. A statistically significant level of \0.05 was
257 considered.
258Results
259Of the 61 patients enrolled (30 in the control group without
260educational intervention and 31 in the intervention group
261with educational intervention), 57 (93.4 %) completed the
262study as planned in the protocol; 4 patients ended prema-
263turely for various reasons (illness or moving to another city).
264No significant differences in terms of baseline clinical
265characteristics were detected between control and inter-
266vention group (Table 1).
267The majority were women (83.6 %), with a mean age of
26847 ± 12.7 years. A mean of 2.5 years had elapsed from the
269onset of symptoms to diagnosis (range 0–8 years). The
270mean time from diagnosis to the study was 10.5 years; only
2714.9 % of patients reported having received health
Table 3 Schedule and contents of educational sessions
Educational session Type of session Content
Visit 1 baseline Patients ? family,
group sessions
Data Collection and baseline Questionnaires
Pathophysiological basis of Cushing’s syndrome
Cause, effect, and origin of hypercortisolismin
Difference between cured and active disease
Description and management of comorbidities that occur in Cushing’s syndrome
Basis of self-care in Cushing’s syndrome.
Visit 2 (1.5 months after
baseline)
Patients group
sessions
Effects, dosage, and side effects of treatments
Risk factors and health care
Type of comorbidities associated with the disease
Difficulties and limitations of self-care
Perception of patient experiences.
Healthstyle instructions: diet, exercise, physical activity, smoke
Specific recommendations for physical activity
Visit 3 (2 months after
baseline)
Patients group
sessions
Banned or restricted food consumption
Role of salt, phosphorus, calcium, magnesium, and fats
Foods allowed and prohibited for each risk factor
Practice on balanced diets
Practical calculation of caloric content
Basic rules for an optimal level of relaxation
Problems and limitation of sexual activity
Strengthen physical activity recommendations
Visit 4 Final visit (2.5 months
after baseline)
Patients ? family,
group sessions
Proper diet, food groups (carbohydrates, protein, saturated and unsaturated fats,
vitamins, water, trace elements, foods rich in calcium, phosphorus, and magnesium,
fiber)
Workshop on preparation of balanced diets
Visit 5 End of the study
(9 months after baseline)
Patients group
sessions
Final data Collection and final Questionnaires
Visit 1 information on themes related to the knowledge of the pathology and comorbidities
Visit 2 information on themes related to the treatment, difficulties in the management of the disease and patient perceptions
Visit 3 information on themes related to the correct management of the disease and healthy living habits
Visit 4 information on nutrition and healthcare habits
Endocrine
123
Journal : Large 12020 Dispatch : 11-9-2015 Pages : 11
Article No. : 737 h LE h TYPESET
MS Code : ENDO-D-15-00568 h CP h DISK4 4
R
E
V
IS
E
D
PR
O
O
F
272 education, despite the long period since diagnosis. There
273 were no differences in waist, waist hip ratio, weight, or
274 blood pressure between groups at the end of the study or
275 changes within groups throughout the study.
276 Nodifferences in thequestionnaires’ scoreswere evidenced
277 between intervention group and control group at baseline.
278 Quality of life
279 The intervention group had a better CushingQoL score
280 compared to control group, at the end of the study
281 (56.47 ± 19.18 vs. 48.49 ± 20.02, p\ 0.01).
282 No changes in the CushingQoL score were evidenced
283 within the intervention group. By contrast, the control
284 group decreased their CushingQoL score from baseline to
285 the end of the study (59.27 ± 19.79 vs. 48.49 ± 20.02,
286 p\ 0.01), indicating a worsening in HRQoL, (Fig. 1).
287 Finally, the subgroup of patients of the intervention group
288 with worse HRQoL at baseline showed an improvement in
289 the CushingQoL score at the end of the study (p\ 0.01).
290 Pain
291 Pain intensity was less in the intervention group than in the
292 control group, at the end of the study (5.00 ± 4.06 vs.
293 5.97 ± 4.72, p\ 0.05).
294 Moreover, the final pain intensity fell in the intervention
295 group compared to its baseline scores (7.21 ± 4.36 vs.
296 5.00 ± 4.06, p\ 0.01). By the contrast, no differences in
297 pain intensity have been evidenced in the control group
298 compared to its baseline scores (Fig. 2).
299 Finally, there was a positive correlation between
300 reduced level of pain and improvement in HRQoL
301 (r = 0.46, p\ 0.05).
302 Physical activity
303 The percentage of high physical activity level was higher in
304 the intervention group compared to control group, at the
305 end of the study (46.4 vs. 10.3 %, p\ 0.01).
306 Moreover, an increase in the percentage of patients with
307 high physical activity level (from 17.9 to 46.4 %,
308 p\ 0.001) was observed in the intervention group. By the
309 contrast, physical activity did not vary from baseline to the
310 end of the study in the control group.
311 Finally, there was a positive correlation between high
312 physical activity level and the improvement in HRQoL
313 (r = 0.89, p\ 0.01).
314 Rest
315 The OSQ indicated insomnia and hypersomnia in CS patients
316 at baseline, without differences between intervention and
317control group. Moreover, no changes were seen between
318baseline and the end of the study in either group.
319However, there was a significant improvement in self-
320reported quantity (= number or hours, 7.53 ± 1.10 vs.
3216.39 ± 1.34, p\ 0.05) and quality of rest (measured as the
322percentage of patients that referred satisfaction with the
323rest, 64 vs. 89 %, p\ 0.05) throughout the study, in the
324intervention group.
325Finally, there was a positive correlation between the
326quantity of rest and the improvement in HRQoL (r = 0.53,
327p = 0.01).
328Healthy lifestyle
329There was more adherence to educational instructions on
330healthy lifestyle in the intervention group compared to
331control group at the end of the study (4.00 ± 0.38 vs.
3322.76 ± 0.29, p\ 0.001).
333Moreover, an improvement in the adherence to educa-
334tional instructions on healthy lifestyle was seen in the
335intervention group at the end of the study compared to
336baseline (3.19 ± 0.32 vs. 4.00 ± 0.38, p\ 0.05). By con-
337trast, adherence worsened in the control group throughout
338the study period (3.00 ± 0.37 vs. 1.66 ± 0.29 p\ 0.05).
339Use of health resources
340The intervention group has lower number of unscheduled
341visits (0.11 ± 0.57 vs. 2.38 ± 1.12 p\ 0.01) and admis-
342sions to the emergency services (0.04 ± 0.09 vs.
3431.55 ± 0.50 p\ 0.05) compared to control group at the
344end of the study.
345Moreover, there was a reduction in unscheduled visits
346(2.15 ± 1.40 vs. 0.11 ± 0.57 p\ 0.01) and in admissions
347to the emergency services (0.55 ± 0.80 vs. 0.04 ± 0.09,
348p\ 0.05) in the intervention group throughout the study
349period. By contrast, the number of unscheduled visits
350increased throughout the study period in the control group
351(1.30 ± 1.40 vs. 2.38 ± 1.12, p\ 0.01), without changes
352in admissions to the emergency services.
353Smoking
354No differences between groups for nicotine dependence
355were observed at baseline or throughout the study; however,
356the number of daily smoked cigarettes tended to be lower in
357the intervention group at the end of the study (p = 0.06).
358Sexual function
359Forty percent of males with CS showed erectile dysfunc-
360tion and 50 % of women had a Hypoactive Sexual Desire
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361 Disorder. However, no differences between groups or
362 within each group in the IIEF 5, FSFI, and B- PFSF scores
363 were evidenced between baseline and the end of the study.
364 Discussion
365 A specific nursing interventional program for patients
366 with CS has been applied in this study, demonstrating
367 an improvement in physical activity, healthy lifestyle
368habits, adherence to therapy, sleep patterns, and a
369reduction in pain level and in use of health resources.
370Furthermore, patients who participated in the educa-
371tional sessions had better HRQoL than patients who did
372not participate, at the end of the study. In particular,
373patients with worse HRQoL at the baseline showed a
374greater improvement at the end of the study, indicating
375that those patients with severe impairment in their
376HRQoL benefit more from the educational intervention
377than the rest.
Fig. 1 CushingQoL
questionnaire scores in control
and in intervention groups at
baseline and at the end of the
study. No differences in the
CushingQoL score were
evidenced at baseline between
the groups. The intervention
group had a better CushingQoL
score than control group, at the
end of the study (p\ 0.01). No
changes in the CushingQoL
score were evidenced in the
intervention group throughout
the study period. The control
group decreased CushingQoL
score throughout the study
period (p\ 0.01)
Fig. 2 Pain intensity in the
control group and in the
intervention group at baseline
and at the end of the study,
evaluated with the SPQ
(Spanish Pain Questionnaire).
No differences in the SPQ score
were evidenced at baseline
between the groups. Pain
intensity was less in the
intervention group than in the
control group at the end of the
study (p\ 0.05). The final pain
intensity fell in the intervention
group throughout the study
period (p\ 0.01). No
differences in pain intensity
were evidenced in the control
group throughout the study
period
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378 CS patients complained that the complex and specific
379 characteristics of their disease and the absence of specific
380 health education made it difficult for them to cope and to
381 carry out their everyday activities. In fact, only 4.9 % of
382 our patients reported any health education over the years,
383 without a clear specificity on CS comorbidities. Thus, the
384 intervention group had a strong motivation which favored
385 following all the education sessions and to improve their
386 healthstyle.
387 This nursing educational intervention prevented deteri-
388 oration of HRQoL in the intervention group, improving
389 indicators of social life, confidence, relaxation, and pain
390 measured by the CushingQoL questionnaire. This ques-
391 tionnaire indicated improvements in different health indi-
392 cators, such as rest and physical activity, suggesting that an
393 appropriate educational intervention in each of them has an
394 additive effect on the final end point, in this case HRQoL.
395 This improvement was particularly evident in older, less
396 educated, unemployed patients, or housewives; interest-
397 ingly, the educational sessions were particularly useful in
398 this group of patients, referred to as the most vulnerable in
399 the literature, and therefore less likely to acquire healthy
400 habits [14, 15, 17, 18, 46].
401 Educational programs are used in a range of chronic
402 illnesses to enable patients to gain personal control and
403 self-efficacy. Studies indicate that educated patients man-
404 age their symptoms more effectively, leading to a better
405 HRQoL, with an enhanced sense of wellbeing and a
406 reduction in healthcare costs [47]. In other words, patient
407 education plays an essential role in promoting safe self-
408 management practice. When developing and applying a
409 competency-based patient education program, patients
410 learn how to manage the disease and its consequent
411 comorbidities; this leads to a better psychological status
412 that also improves their physical status [16, 48]. The
413 worsening in HRQol in the control group is an intriguing
414 point, and we do not have a clear explanation. It may be
415 related to the lack of a specific education. The educational
416 intervention focused on multiple dimensions that all toge-
417 ther helped to improve HRQol; by contrast, routine medical
418 approach could only deal with the medical dimension.
419 The results obtained in terms of HRQoL suggest new
420 research fields, such as the relationship between the edu-
421 cational programs and the different bio-psycho-social
422 characteristics of patients; they also suggest the need to use
423 different health resources as nursing programs.
424 The reduction in perceived pain intensity in the inter-
425 vention group after the educational sessions of our study
426 may be related to different causes, approached during the
427 sessions; these include a greater adherence to analgesic
428 treatment, learning healthy posture patterns and increased
429 daily physical activity. In addition, this reduction of pain
430 generated a positive impact on other areas of health and
431HRQoL, such as rest, fatigue, and physical activity, as
432confirmed by the patients and as evidenced in similar studies
433in the literature [49, 50]. It is known that specific exercise
434protocols and walking programs have a positive effect on the
435HRQoL of elderly individuals with osteoarthritis [51, 52].
436Insomnia is another problem in CS patients, creating a
437state of fatigue and anxiety that limits their HRQoL. The
438significant improvement in self-reported quantity (number
439of hours) and quality of rest (satisfaction) throughout the
440study in the intervention group clearly improved HRQoL.
441Apart from the intervention on sleep habits, the reduction
442of pain and the increased physical activity may also have
443positively influenced the sleep quality and quantity. Our
444study found a significant increase in the percentage of
445patients with a high physical activity level in the inter-
446vention group; due to the motivation, they had during the
447educational sessions. Data are emerging regarding the
448positive effect of physical activity level on rest in chronic
449diseases; moreover, the relationship between sleep quality
450and physical activity is bidirectional [53, 54].
451Regarding nutritional habits, the intervention group
452learned specific diet recommendations and correct eating
453habits during the sessions, which included a workshop on
454preparation of balanced diets. Moreover, the active par-
455ticipation of the family in the group sessions favored
456patient’s engagement in changing eating behaviors. The
457intervention group significantly improved compliance to
458healthy lifestyle food habits at the end of the study; by
459contrast, the control group worsened during the study
460period. This is in line with literature data on educational
461processes in chronic diseases leading to changes in eating
462habits [55–57].
463Regarding sexuality, even if there was not improvement
464after the educational program it is important to mention
465that a significant percentage of patients (both men and
466women) reported alterations, mainly erectile dysfunction
467and low sexual desire. As far as we know, this is the first
468study to address this issue with validated instruments. Our
469results indicate the convenience of evaluating these prob-
470lems in clinical practice and of performing further inter-
471ventions to improve sexual function in patients with CS.
472Finally, our study evidenced a decrease in the number of
473admissions and unscheduled visits in the intervention group
474during the educational program, with the consequent
475decrease in consumed health resources.
476Nine patients had hypopituitarism (5 partial and 4 total),
477equally distributed in the control and the intervention
478group, all were on stable replacement therapy started at
479least 2 years before the study. Therefore, hypopituitarism
480would not appear to influence the results of this educational
481program.
482There were no differences in the type and severity of
483comorbidities between the control and intervention group,
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484 neither at baseline nor at the end of the study, suggesting
485 that they did not affect the investigated variables. However,
486 one might have expected that the number of comorbidities,
487 especially cardiometabolic, would have decreased in the
488 educational group, although this cannot be excluded in the
489 long term.
490 Limitations of our study included a limited time of the
491 educational sessions; a longer educational program might
492 have helped the patients in reducing their cardiometabolic
493 comorbidities (reducing BMI and weight) and to improve
494 further their HRQoL. Indeed the important role of the
495 nursing management in education is well known, in par-
496 ticular that a structural evaluation of cardiovascular risk
497 factors and an integrated nurse-led approach can success-
498 fully reduce risk in cardiovascular patients [58].
499 The number of daily smoked cigarettes only tended to
500 be lower in the intervention group; possibly a longer time
501 of educational sessions might have helped to stop smoking.
502 All active patients were on medical therapy, and
503 eucortisolemia was confirmed in all patients. In ‘‘naı¨ve’’
504 patients, the educational sessions would probably have
505 been more effective. However, on one hand, it is not ethic
506 to maintain naı¨ve of treatment a CS patient for 9 months,
507 and on the other hand, controlling this condition during the
508 study would influence the results of the program.
509 Regression analysis could have been done; however, we
510 preferred to do t tests because regression analysis would
511 evaluate the change along the time and not the values at
512 baseline or at the end of the study.
513 Finally, the number of patients studied is relatively
514 small despite including patients from two 2 reference
515 centers, a problem which is practically unavoidable in rare
516 diseases, especially if followed up long-term over the
517 years.
518 Conclusions
519 A specific nursing educational program, addressed to CS
520 patients, obtained a positive modification of different living
521 habits, achieving an improvement of physical activity,
522 healthy lifestyle habits, sleep patterns, and reduction in
523 pain level. Even if the program only included 4 educational
524 sessions, it considerably influenced patient‘s HRQoL. In
525 particular, patients with worse HRQol at baseline showed a
526 greater improvement at the end of the study. Moreover, the
527 educational sessions allowed not only clinical improve-
528 ment, but also a reduction of hospital admissions and
529 unscheduled visits. Finally, the brief nature of the program
530 makes it as a good candidate to be used in clinical man-
531 agement of patients with CS.
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